T 细胞参与双特异性抗体 (TCB) 疗法已成为一种有前景的免疫治疗方法，可有效地重新定向效应 T 细胞以选择性地消除肿瘤细胞。 TCB 的治疗潜力已得到充分认可，特别是近年来多种 TCB 被批准用于治疗血液系统恶性肿瘤以及一些实体瘤。然而，TCB在治疗实体瘤时遇到多重挑战，例如靶向脱瘤毒性、细胞因子释放综合征（CRS）和免疫抑制肿瘤微环境中的T细胞功能障碍，所有这些都可能影响其治疗效果。在这篇综述中，我们总结了 TCB 用于实体瘤治疗的临床数据，强调了面临的挑战，并根据当前临床和临床前研究的新兴策略讨论了潜在的解决方案。这些解决方案包括TCB结构优化、目标选择和组合策略。这项综合分析旨在指导 TCB 从设计到临床应用的开发，应对癌症免疫疗法不断发展的前景。版权所有 © 2024 Elsevier B.V. 保留所有权利。

T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate tumor cells. The therapeutic potential of TCBs has been well recognized, particularly with the approval of multiple TCBs in recent years for the treatment of hematologic malignancies as well as some solid tumors. However, TCBs encounter multiple challenges in treating solid tumors, such as on-target off-tumor toxicity, cytokine release syndrome (CRS), and T cell dysfunction within the immunosuppressive tumor microenvironment, all of which may impact their therapeutic efficacy. In this review, we summarize clinical data on TCBs for solid tumor treatment, highlight the challenges faced, and discuss potential solutions based on emerging strategies from current clinical and preclinical research. These solutions include TCB structural optimization, target selection, and combination strategies. This comprehensive analysis aims to guide the development of TCBs from design to clinical application, addressing the evolving landscape of cancer immunotherapy.Copyright © 2024 Elsevier B.V. All rights reserved.